Exviera, Viekirax combination added benefit for patients with HCV without cirrhosis
the MALACHITE I and II clinical studies, where patients with HCV genotype 1a or 1b without cirrhosis were dosed with Exviera (dasabuvir, AbbVie) in combination with Viekirax (ombitasvir/paritaprevir/ritonavir, AbbVie) with or without ribavirin, and compared with patients treated with a combination of Incivek
the MALACHITE I and II clinical studies, where patients with HCV genotype 1a or 1b without cirrhosis were dosed with Exviera (dasabuvir, AbbVie) in combination with Viekirax (ombitasvir/paritaprevir/ritonavir, AbbVie) with or without ribavirin, and compared with patients treated with a combination of Incivek